Vaccine Adverse Reaction Clinical Trial
Official title:
Safety and Immunogenicity of Oxford AstraZeneca Vaccine in Zagazig University Hospital Health-care Workers
After SARS-COV-2 inactivated vaccine authorization for use in different countries including Egypt, investigating its immunogenicity, safety, and efficacy in preventing COVID-19 infection is highly needed. In Egypt, immunization of HCWs in isolation hospitals by SARS-COV-2 inactivated vaccine is now a national priority. Moreover, data and reports regarding the application of vaccine are still limited and deficient.
This study will be conducted at Zagazig University hospital. Laboratory work will be implemented at Immunology Research Laboratory at Microbiology and Immunology Department, Faculty of Medicine, Zagazig University. A representative sample will be drawn from healthcare workers (HCWs) at Zagazig University Hospital. Assessment of inclusion and exclusion criteria by history taking. Blood samples will be drawn from HCWs by direct venipuncture before the start of immunization and 14 days after immunization. The incidence of any adverse reactions after each immunization will be recorded. SARS-CoV-2 neutralizing antibodies will be detected by enzyme-linked immunosorbent assay. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03966391 -
Effectiveness of CARD for Improving School-Based Immunizations
|
N/A | |
| Completed |
NCT04530357 -
Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine
|
Phase 1/Phase 2 | |
| Terminated |
NCT03966300 -
Improving the School Vaccination Experience: What CARDs Are You Going to Play?
|
N/A | |
| Active, not recruiting |
NCT06286488 -
Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza
|
Phase 4 | |
| Recruiting |
NCT05546502 -
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children
|
Phase 3 | |
| Active, not recruiting |
NCT05483725 -
Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
|
||
| Completed |
NCT03600428 -
Safety of LAIV4 in Children With Asthma
|
Phase 4 | |
| Completed |
NCT03400878 -
Comparing Morbidity and Mortality Effects of Two Different Strains of BCG
|
Phase 4 | |
| Completed |
NCT05116748 -
COVID19 Vaccine in SOT Adult Recipients
|
||
| Not yet recruiting |
NCT05171946 -
Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults
|
Phase 1 | |
| Recruiting |
NCT05128721 -
Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19)
|
Phase 1 | |
| Withdrawn |
NCT04894682 -
Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor
|
||
| Not yet recruiting |
NCT05387252 -
Glucoside- and Rutinoside-rich Crude Material for Relieving Side Effects of COVID-19 Vaccines
|
N/A | |
| Active, not recruiting |
NCT04801667 -
Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients
|
Phase 4 | |
| Not yet recruiting |
NCT05283902 -
Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
|
||
| Recruiting |
NCT05095844 -
National Vaccine Adverse Event Reporting Survey and Etiology
|
||
| Recruiting |
NCT05315856 -
Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms
|
||
| Recruiting |
NCT05898464 -
Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV
|
Phase 4 | |
| Recruiting |
NCT05212792 -
Genomics and COVID-19 Vaccine Adverse Events
|
||
| Recruiting |
NCT05258708 -
COVID-19 Vaccine Reactogenicity and Immunogenicity
|